You are here: Industry Insights > Keytruda

News List

Thousands of lung cancer patients to get NHS access to Keytruda pharmatimes
November 23, 2018
MSD’s Keytruda should be funded on the NHS via the Cancer Drugs Fund for patients with the certain forms of lung cancer, according to draft guidance from the National Institute for Health and Care Excellence.
MSD's Keytruda to treat melanoma in England on the Cancer Drugs Fund pharmafile
November 20, 2018
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it has emerged.
MSD’s Keytruda shows benefit in oesophageal cancer trial pharmatimes
November 19, 2018
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
Merck's Keytruda picks up first-in-class survival win in esophageal cancer fiercepharma
November 15, 2018
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
Merck's Keytruda picks up first-in-class survival win in esophageal cancer fiercepharma
November 15, 2018
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
MSD’s Keytruda approved for liver cancer pharmatimes
November 14, 2018
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Merck & Co.'s Keytruda cleared by FDA for certain treatment-experienced patients with HCC pharmafile
November 12, 2018
Merck & Co. on Friday said Keytruda (pembrolizumab) has received accelerated approval from the FDA for the treatment of hepatocellular carcinoma (HCC) in patients
Amazing Monthly Sales Performance of Opdivo and Keytruda in China Xiaoyaowan
November 06, 2018
It was revealed that by September 30, i.e., about one month after the marketing in China, the sales revenue of the two anti-PD-1 monoclonal antibody drugs: Opdivo and Keytruda separately reached RMB 190 million and RMB 150 million, showing amazing perform
US expands reach of Keytruda in NSCLC pharmatimes
November 05, 2018
US regulators have approved MSD’s Keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of ...
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial pharmatimes
October 25, 2018
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS)...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page